heartburn news from FiercePharma
News
SPOTLIGHT: Wyeth sales boosted by Enbrel
Despite major erosion in sales of its heartburn blockbuster Protonix, Wyeth managed to beat Wall Street's expectations for first-quarter earnings, posting a $1.2 billion profit on a 6 percent Read more...
AstraZeneca, Ranbaxy settle Nexium fight
AstraZeneca investors were jumping for joy this morning when the drugmaker announced it had played Let's Make a Deal with Indian generics maker Ranbaxy. The copycat company agreed to wait till 2014 Read more...
Wyeth makes its own Protonix copy
Wyeth decided to beat the copycats to the punch. The drug maker will launch its own generic version of the blockbuster heartburn med Protonix, more than two years ahead of its patent expiration. Read more...
Dexcel gets right to sell copycat Prilosec
The fight is over. Over-the-counter drug distributor Perrigo said its partner Dexcel Pharma Technologies has settled patent litigation with AstraZeneca over the heartburn med Prilosec OTC. The Read more...
Heartburn drug use in kids skyrockets
First diabetes, then high blood pressure, and now heartburn? Kids are turning up with more and more adult ailments these days; consider a new surge in use of heartburn drugs among the 18-and-under Read more...
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight